Log In
BCIQ
Print this Print this
 

Viekirax, ombitasvir/paritaprevir/ritonavir (Technivie)

Also known as: paritaprevir (ABT-450) plus ritonavir/ombitasvir (ABT-267)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionTablets containing ombitasvir, an HCV NS5A protein inhibitor, paritaprevir, an HCV NS3/4A protease inhibitor, and ritonavir, an HIV protease inhibitor
Molecular Target HCV NS3/4A protease complex ; HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor; HCV NS3 protease inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat adult patients with chronic HCV genotype 1 infection, including those with compensated liver cirrhosis; Treat chronic HCV genotype 1 infection; Treat chronic HCV genotype 1 infection in treatment-naïve patients with severe renal impairment; Treat chronic HCV genotype 1b and 4 infections; Treat chronic HCV genotype 1b infection; Treat chronic HCV genotype 1b infection in patients with compensated liver cirrhosis; Treat chronic HCV genotype 4 infection; Treat chronic HCV genotypes 1 and 4 infection
Regulatory Designation U.S. - Priority Review (Treat chronic HCV genotype 1 infection)
PartnerEnanta Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today